MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 208230 | Name: Conjugate linker 1

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Conjugate linker 1 crossing linking peptides/proteins with other molecules

Chemical Structure

Conjugate linker 1
CAS#1637561-55-7

Theoretical Analysis

MedKoo Cat#: 208230

Name: Conjugate linker 1

CAS#: 1637561-55-7

Chemical Formula: C12H11NO7

Exact Mass: 281.0536

Molecular Weight: 281.22

Elemental Analysis: C, 51.25; H, 3.94; N, 4.98; O, 39.82

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Conjugate linker1, Conjugate-linker 1, Conjugate-linker-1
IUPAC/Chemical Name
(2,5-Dioxopyrrolidin-1-yl) 3-(4-methyl-2,5-dioxofuran-3-yl)propanoate
InChi Key
LSZZJVWSEOVRNO-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H11NO7/c1-6-7(12(18)19-11(6)17)2-5-10(16)20-13-8(14)3-4-9(13)15/h2-5H2,1H3
SMILES Code
O=C(ON1C(CCC1=O)=O)CCC2=C(C)C(OC2=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 281.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018 Jan;9(1):33-46. doi: 10.1007/s13238-016-0323-0. Epub 2016 Oct 14. PMID: 27743348; PMCID: PMC5777969. 2: Alas M, Saghaeidehkordi A, Kaur K. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. J Med Chem. 2021 Jan 14;64(1):216-232. doi: 10.1021/acs.jmedchem.0c01530. Epub 2020 Dec 31. PMID: 33382619; PMCID: PMC8610607. 3: Kufka R, Rennert R, Kaluđerović GN, Weber L, Richter W, Wessjohann LA. Synthesis of a tubugi-1-toxin conjugate by a modulizable disulfide linker system with a neuropeptide Y analogue showing selectivity for hY1R-overexpressing tumor cells. Beilstein J Org Chem. 2019 Jan 10;15:96-105. doi: 10.3762/bjoc.15.11. PMID: 30680044; PMCID: PMC6334802. 4: Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019 Aug/Sep;11(6):987-995. doi: 10.1080/19420862.2019.1632115. Epub 2019 Jul 18. PMID: 31208270; PMCID: PMC6748572. 5: Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014 Jan-Feb;6(1):34-45. doi: 10.4161/mabs.27022. PMID: 24423619; PMCID: PMC3929453. 6: Gymnopoulos M, Betancourt O, Blot V, Fujita R, Galvan D, Lieuw V, Nguyen S, Snedden J, Stewart C, Villicana J, Wojciak J, Wong E, Pardo R, Patel N, D'Hooge F, Vijayakrishnan B, Barry C, Hartley JA, Howard PW, Newman R, Coronella J. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68. doi: 10.1002/1878-0261.12600. Epub 2019 Dec 3. PMID: 31736230; PMCID: PMC6944112. 7: Wei D, Yu W, Hu C, Shen L, Hu T. The phenyl linker markedly increases the immunogenicity of the pneumococcal polysaccharide conjugate vaccine. Biotechnol Lett. 2018 Aug;40(8):1263-1270. doi: 10.1007/s10529-018-2575-7. Epub 2018 May 25. PMID: 29802568. 8: Cheng X, Li J, Tanaka K, Majumder U, Milinichik AZ, Verdi AC, Maddage CJ, Rybinski KA, Fernando S, Fernando D, Kuc M, Furuuchi K, Fang F, Uenaka T, Grasso L, Albone EF. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti- human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675. doi: 10.1158/1535-7163.MCT-17-1215. Epub 2018 Sep 27. PMID: 30262588. 9: Abedi M, Cohan RA, Mahboudi F, Faramarzi MA, Fazel R, Damavandi N, Ardestani MS, Davami F. Novel trastuzumab-DM1 conjugate: Synthesis and bio-evaluation. J Cell Physiol. 2019 Aug;234(10):18206-18213. doi: 10.1002/jcp.28453. Epub 2019 Mar 10. PMID: 30854662. 10: Shan L. 64Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-9-aminonanoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2. 2011 Jan 2 [updated 2011 Jan 25]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 21290625.

View History

Artemisinin B

Artemisinin B

Benzyl-PEG6-THP

Benzyl-PEG6-THP

Sematilide

Sematilide